Skip to content
OpenCapital
Get started

Citius Pharmaceuticals CTXR Q1 2026 earnings

Reported May 15, 2026 · Before market open

Revenue$1.7MMiss by $8.6MDiluted EPS-$0.95Miss by $0.67
Revenue estimate$10.2M
EPS estimate-$0.28

Next report

Aug 11, 2026 (in a month)
Revenue estimate$5.5M
EPS estimate-$0.36

Versus estimates

Revenue

Q1 2026$1.7MMiss by $8.6M
Q4 2025$3.9MMiss by $14.1MQ3 2025$3.9M

Diluted EPS

Q1 2026-$0.95Miss by $0.67
Q4 2025-$0.38Miss by $0.81Q3 2025-$0.44Miss by $0.20Q2 2025-$0.80Miss by $0.56Q1 2025-$1.27Miss by $0.19Q4 2024-$1.30Miss by $0.05

Ask the moment Citius Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Citius Pharmaceuticals report Q1 2026 earnings?
Citius Pharmaceuticals (CTXR) reported Q1 2026 earnings on May 15, 2026 before market open.
What were Citius Pharmaceuticals's Q1 2026 revenue and EPS?
Citius Pharmaceuticals reported revenue of $1.7M and diluted EPS of $-0.95 for Q1 2026.
Did Citius Pharmaceuticals beat estimates in Q1 2026?
Revenue missed the consensus estimate of $10.2M by $8.6M. EPS missed the consensus estimate of $-0.28 by $0.67.
How did Citius Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 25.2% from $-1.27.
Where can I find Citius Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-057876) and the 10-Q periodic report (0001213900-26-057842) directly on SEC EDGAR. The filing index links above go to sec.gov.